Economic Burden of Specific Diseases

The economic burden of a specific disease is the total cost it imposes on a population — the medical resources used to treat it plus the production lost because of it. Disease-specific cost-of-illness studies, such as the recurring estimates of the cost of diabetes, apply standard costing methods to a single condition so its economic footprint can be sized and compared.

Definition

The economic burden of a specific disease is the aggregate value of resources consumed and production lost because of that disease in a defined population and period, estimated through a disease-focused cost-of-illness study.

Scope

The entry covers how cost-of-illness methods are applied to individual diseases: the cost components included (direct medical, direct non-medical, and indirect), prevalence-based versus incidence-based costing, attribution of costs to the disease, and the interpretive cautions that apply when comparing estimates. It is a methodological reference and does not give clinical or treatment advice.

Core questions

• Which cost components belong in a disease-specific burden estimate?
• How are costs attributed to one disease rather than to coexisting conditions?
• What is the difference between prevalence-based and incidence-based costing?
• Why should disease cost estimates be compared with caution?

Key concepts

• Cost-of-illness study
• Direct medical and non-medical costs
• Indirect (productivity) costs
• Prevalence-based versus incidence-based costing
• Cost attribution and attributable fraction
• Top-down versus bottom-up costing
• Study perspective

Mechanisms

A disease-specific cost-of-illness study first defines the population, time horizon, and perspective, then enumerates and values the resources attributable to the disease. Direct costs cover medical care (hospitalisation, drugs, outpatient visits) and non-medical items (such as transport); indirect costs cover lost productivity from morbidity and premature death. Costs may be assembled top-down from aggregate expenditure data or bottom-up from individual resource use. A prevalence-based study totals costs in a single year across everyone with the disease, while an incidence-based study follows new cases forward over their lifetime. Care is needed to attribute only the costs caused by the disease, separating them from those of coexisting conditions.

Clinical relevance

Disease-specific burden estimates describe how much a condition costs a health system and society, supporting planning, advocacy, and the inputs to economic evaluation. They are descriptive population-level figures and are not used to guide the diagnosis or treatment of an individual patient.

Epidemiology

Chronic, non-communicable diseases account for a large and growing share of disease-specific costs in most countries; diabetes is a frequently studied example, with national estimates documenting substantial and rising direct and indirect costs.

Evidence & guidelines

Disease cost estimates rest on cost-of-illness methods set out in health-economics texts; comparability across studies is limited because perspective, cost components, costing approach, and attribution differ. Transparent reporting of these choices is expected, and figures are best read alongside their methods rather than at face value.

History

Cost-of-illness accounting for individual diseases grew alongside the broader cost-of-illness tradition in health economics, maturing as chronic diseases came to dominate health spending. Recurring national studies — for example successive estimates of the cost of diabetes — illustrate how the same methods are applied and updated for one condition over time.

Debates

How should costs be attributed to a single disease?

People often have several conditions at once, so deciding which costs are caused by the index disease — rather than by comorbidities — strongly affects the estimate and depends on the attribution method chosen.

Are disease cost estimates comparable?

Because studies differ in perspective, included cost components, and costing approach, headline figures for the same disease can diverge widely, so cross-study comparison requires reading the methods closely.

Key figures

• Michael Drummond
• Marc Koopmanschap
• Derek Yach

Seminal works

• ada-2018
• yach-2004

Frequently asked questions

What does the economic burden of a disease include?

It includes the direct costs of treating the disease (such as hospital, drug, and care costs) and the indirect costs of production lost because of illness and premature death, summed for a defined population and period.

Why do different studies report very different costs for the same disease?

Because they make different choices about perspective, which cost components to count, how to attribute costs to the disease, and whether to cost on a prevalence or incidence basis, so estimates are best interpreted alongside their methods.